Mycobutin (Rifabutin)

Rifabutin acts on mycobacterial infections and is employed in several clinical settings.

• Mycobacterium avium complex (MAC) infection in HIV‑positive patients: reduces bacterial load and helps prevent disease progression.
• Prophylaxis of MAC disease: administered to high‑risk individuals to prevent infection.
• Tuberculosis (as part of combination therapy): contributes to bacterial eradication when combined with other antitubercular agents.

• Rifabutin binds to the β‑subunit of bacterial DNA‑dependent RNA polymerase, blocking the initiation of RNA synthesis. This inhibition suppresses transcription of essential genes in mycobacteria, leading to bacteriostatic or bactericidal effects depending on concentration and exposure time.

Rifabutin may cause a range of adverse reactions.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Vomiting: occasional episodes after dosing.
• Abdominal pain: cramping or discomfort in the stomach area.
• Diarrhea: loose stools that may be transient.
• Rash: skin redness or mild itching.
• Fever: low‑grade temperature elevation.

Serious or Rare Side Effects

• Neutropenia: significant drop in white blood cells requiring monitoring.
• Hepatotoxicity: elevated liver enzymes or jaundice.
• Severe skin reactions (e.g., Stevens‑Johnson syndrome): requires immediate medical attention.
• Thrombocytopenia: reduced platelet count leading to bleeding risk.
• Hemolytic anemia: destruction of red blood cells.
• Severe hypersensitivity: anaphylactic‑type reactions.

Before initiating Rifabutin therapy, consider the following precautions.

• Assess liver function: obtain baseline hepatic enzymes and monitor periodically.
• Monitor complete blood count: watch for neutropenia or thrombocytopenia.
• Avoid use in patients with known hypersensitivity to rifamycins.
• Use caution in HIV‑positive patients receiving protease inhibitors due to interaction potential.
• Store at room temperature: keep in the original pack, protect from moisture and light.

Rifabutin interacts with several drug classes; careful management is required.

Major Interactions (Avoid)

• Protease inhibitors (e.g., ritonavir): may raise rifabutin levels and increase toxicity.
• Macrolide antibiotics (e.g., clarithromycin, azithromycin): can markedly increase rifabutin concentrations.
• Antiretroviral agents (e.g., efavirenz): may lower rifabutin exposure, reducing efficacy.

Moderate Interactions (Monitor Closely)

• Warfarin: rifabutin can enhance anticoagulant effect, requiring INR monitoring.
• Oral contraceptives: effectiveness may be reduced, advise additional non‑hormonal contraception.